Genprex (NASDAQ:GNPX) Issues Earnings Results

Genprex (NASDAQ:GNPX) released its quarterly earnings data on Wednesday. The company reported ($0.64) earnings per share (EPS) for the quarter, Zacks reports.

Genprex Stock Performance

Shares of GNPX traded down $0.02 during mid-day trading on Friday, reaching $0.84. 163,763 shares of the company’s stock traded hands, compared to its average volume of 1,002,734. The business’s 50-day moving average price is $1.45 and its 200-day moving average price is $2.41. The stock has a market capitalization of $8.75 million, a P/E ratio of -0.03 and a beta of -0.94. Genprex has a 12 month low of $0.81 and a 12 month high of $55.00.

Institutional Trading of Genprex

A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP grew its holdings in shares of Genprex (NASDAQ:GNPX) by 11.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.